Cargando…

Fulvestrant treatment alters MDM2 protein turnover and sensitivity of human breast carcinoma cells to chemotherapeutic drugs

The human homologue of mouse double minute 2 (MDM2) is overexpressed in tumors and contributes to tumorigenesis through inhibition of p53 activity. We investigated the effect of the anti-estrogen fulvestrant on MDM2 expression and sensitivity of estrogen receptor positive human breast cancer cell li...

Descripción completa

Detalles Bibliográficos
Autores principales:	Dolfi, Sonia C., Jäger, Adriana V., Medina, Daniel J., Haffty, Bruce G., Yang, Jin-Ming, Hirshfield, Kim M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	2014
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5500211/ https://www.ncbi.nlm.nih.gov/pubmed/24747123 http://dx.doi.org/10.1016/j.canlet.2014.04.009

Ejemplares similares

A Review of Fulvestrant in Breast Cancer
por: Nathan, Mark R., et al.
Publicado: (2017)

Economic Evaluation for Palbociclib Plus Fulvestrant vs Ribociclib Plus Fulvestrant and Abemaciclib Plus Fulvestrant in Endocrine-Resistant Advanced or Metastatic Breast Cancer in Italy
por: Colombo, Giorgio Lorenzo, et al.
Publicado: (2023)

Emerging Role of Genomic Rearrangements in Breast Cancer: Applying Knowledge from Other Cancers
por: Paratala, Bhavna S., et al.
Publicado: (2016)

Retrospective Evaluation of Fulvestrant Efficacy and Clinical Results in Patients Using Fulvestrant
por: Kut, Engin, et al.
Publicado: (2023)

Fulvestrant: pharmacokinetics and pharmacology
por: Robertson, J F R, et al.
Publicado: (2004)

Fulvestrant Plus Vistusertib vs Fulvestrant Plus Everolimus vs Fulvestrant Alone for Women With Hormone Receptor–Positive Metastatic Breast Cancer: The MANTA Phase 2 Randomized Clinical Trial
por: Schmid, Peter, et al.
Publicado: (2019)

Fulvestrant and the sequential endocrine cascade for advanced breast cancer
por: Johnston, S
Publicado: (2004)

Oestradiol measurement during fulvestrant treatment for breast cancer
por: Owen, Laura J., et al.
Publicado: (2019)

Silencing MED1 Sensitizes Breast Cancer Cells to Pure Anti-Estrogen Fulvestrant In Vitro and In Vivo
por: Zhang, Lijiang, et al.
Publicado: (2013)

MiR-214 increases the sensitivity of breast cancer cells to tamoxifen and fulvestrant through inhibition of autophagy
por: Yu, Xinfeng, et al.
Publicado: (2015)

Fulvestrant in advanced breast cancer: evidence to date and place in therapy
por: Boér, Katalin
Publicado: (2017)

Serum Biomarkers for the Detection of Cardiac Toxicity after Chemotherapy and Radiation Therapy in Breast Cancer Patients
por: Tian, Sibo, et al.
Publicado: (2014)

Riluzole exerts distinct antitumor effects from a metabotropic glutamate receptor 1-specific inhibitor on breast cancer cells
por: Dolfi, Sonia C, et al.
Publicado: (2017)

Role of Biomarkers in the Development of PARP Inhibitors
por: Ganguly, Bratati, et al.
Publicado: (2016)

A method to detect fulvestrant interference in estradiol in breast cancer patients
por: Brito, Margarida, et al.
Publicado: (2023)

Mechanical Alteration Associated With Chemotherapeutic Resistance of Breast Cancer Cells
por: Park, Soyeun
Publicado: (2018)

Fulvestrant-induced toxic epidermal necrolysis
por: Morales-Conde, Macarena, et al.
Publicado: (2019)

RET rearrangements are actionable alterations in breast cancer
por: Paratala, Bhavna S., et al.
Publicado: (2018)

Phenotype plasticity and altered sensitivity to chemotherapeutic agents in aggressive prostate cancer cells
por: Paxson, Allan I., et al.
Publicado: (2023)

Quality of life with palbociclib plus fulvestrant versus placebo plus fulvestrant in postmenopausal women with endocrine-sensitive hormone receptor-positive and HER2-negative advanced breast cancer: patient-reported outcomes from the FLIPPER trial
por: Tibau, Ariadna, et al.
Publicado: (2023)

The Exposure of Breast Cancer Cells to Fulvestrant and Tamoxifen Modulates Cell Migration Differently
por: Lymperatou, Dionysia, et al.
Publicado: (2013)

Fulvestrant-induced expression of erbB3 and erbB4 sensitizes ER-positive breast cancer cells to heregulins
por: Hutcheson, IR, et al.
Publicado: (2010)

The role of MDM2 and MDM4 in breast cancer development and prevention
por: Haupt, Sue, et al.
Publicado: (2017)

Comparative efficacy & safety of buparlisib plus fulvestrant, fulvestrant plus dalpiciclib, and ribociclib plus letrozole for postmenopausal, hormone receptor-positive, and HER2-negative breast cancer
por: Liu, Qi, et al.
Publicado: (2023)

PTCH-1 and MDM2 expression in ameloblastoma from a West African sub-population: implication for chemotherapeutics
por: Udeabor, Samuel Ebele, et al.
Publicado: (2015)

GSDME Increases Chemotherapeutic Drug Sensitivity by Inducing Pyroptosis in Retinoblastoma Cells
por: Li, Fang, et al.
Publicado: (2022)

Modeling Expression Plasticity of Genes that Differentiate Drug-sensitive from Drug-resistant Cells to Chemotherapeutic Treatment
por: Wang, Ningtao, et al.
Publicado: (2014)

Revisiting Fulvestrant Dosing in Uncertain Economic Times
por: Patel, Amol, et al.
Publicado: (2021)

Smac/DIABLO enhances the therapeutic potential of chemotherapeutic drugs and irradiation, and sensitizes TRAIL-resistant breast cancer cells
por: Fandy, Tamer E, et al.
Publicado: (2008)

Berberine attenuates XRCC1‐mediated base excision repair and sensitizes breast cancer cells to the chemotherapeutic drugs
por: Gao, Xingjie, et al.
Publicado: (2019)

A comparison of fulvestrant plus a targeted agent with fulvestrant alone in hormone receptor-positive advanced breast cancer that progressed on prior endocrine therapy: a meta-analysis
por: Xu, Liang, et al.
Publicado: (2018)

Acquisition of anoikis resistance in human osteosarcoma cells does not alter sensitivity to chemotherapeutic agents
por: Díaz-Montero, C Marcela, et al.
Publicado: (2005)

Associations of MDM2 and MDM4 Polymorphisms with Early-Stage Breast Cancer
por: Bartnykaitė, Agnė, et al.
Publicado: (2021)

Early circulating tumor DNA dynamics and clonal selection with palbociclib and fulvestrant for breast cancer
por: O’Leary, Ben, et al.
Publicado: (2018)

Clinical utility of fulvestrant in the treatment of breast cancer: a report on the emerging clinical evidence
por: Rocca, Andrea, et al.
Publicado: (2018)

Palbociclib and Fulvestrant Act in Synergy to Modulate Central Carbon Metabolism in Breast Cancer Cells
por: Warth, Benedikt, et al.
Publicado: (2019)

Clinical activity of fulvestrant in metastatic breast cancer previously treated with endocrine therapy and/or chemotherapy
por: Heo, Mi Hwa, et al.
Publicado: (2019)

RF05 | PSUN341 Role of sirtuins in breast cancer cells response to Fulvestrant
por: Sengupta, Surojeet, et al.
Publicado: (2022)

Predicting Hyperglycemia Among Patients Receiving Alpelisib Plus Fulvestrant for Metastatic Breast Cancer
por: Ge, Xuan, et al.
Publicado: (2023)

Impact of the MDM2 splice-variants MDM2-A, MDM2-B and MDM2-C on cytotoxic stress response in breast cancer cells
por: Huun, Johanna, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_tfodoq9v0h97agquieg6d5tt8e